Calcium channel blockers in psychiatric disorders: A review of the literature

Canadian Journal of Psychiatry

Volumn 44, Issue 7, 1999, Pages 658-664

  Hollister, Leo E ^a,c   Garza Trevino, Enrique Sergio ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b San Antonio Mood Disorders Clinic   (United States)

^c NONE   (United States)

Author keywords

Calcium channel blockers; Depression; Mania; Nifedipine; Schizophrenia; Tardive dyskinesia; Verapamil

Indexed keywords

AMOXAPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FLUNARIZINE; LITHIUM; NEUROLEPTIC AGENT; NIFEDIPINE; NIMODIPINE; TRANQUILIZER; TRAZODONE; VERAPAMIL;

ALZHEIMER DISEASE; BIPOLAR DEPRESSION; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; HUMAN; MANIA; MEDICAL LITERATURE; MENTAL DISEASE; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 0032758961     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379904400702     Document Type: Review

References (73)

1. Dubovsky SL, Buzan RD. Novel alternatives and supplements to lithium and anti-convulsants for bipolar affective disorder. J Clin Psychiatry 1997;58:224-42.
2. Carman JS, Wyatt RJ. Calcium pacesetting the periodic psychosis. Am J Psychiatry 1979;136:1035-9.
3. Could RJ, Murphy KM, Reynolds IJ, Snyder SH. Antischizophrenic drugs of the diphenylbutyl-piperidine type act as calcium channel antagonists. Proc Natl Acad Sci USA 1983;80:5122-5.
4. Stanley RF. The calcium channel and the organization of the presynaptic transmitter release face. Trends Neurosci 1997;20:404-9.
5. Weston PG. Magnesium as a sedative. Am J Psychiatry 1921-22;1:637-8.
6. Caillard V. Masse G. Traitement de la manie par un inhibiteur calcique. Étude préliminaire. Encephale 1982;VVI;587-94.
7. Goldstein JA. Calcium and neurotransmission [letter]. Biol Psychiatry 1984;19:406.
8. Gitlin MJ, Weisse J. Verapamil as maintenance treatment in bipolar illness: a case report. J Clin Psychopharmacol 1984;4:341-3.
9. Caillard V. Treatment of mania using a calcium antagonist-preliminary trial. Neuropsychobiology 1985:14:23-6.
10. Brotman AW, Farhadi AM, Gelenberg AJ. Verapamil treatment of acute mania. J Clin Psychiatry 1986;47:136-8.
11. Solomon L, Williamson P. Verapamil in bipolar illness. Can J Psychiatry 1986:31:442-4.
12. Kennedy S, Ozersky S, Robillard M. Refractory bipolar illness may not respond to verapamil [letter]. J Clin Psychopharmacology 1986;6:316-7.
13. Barton BM, Gitlin MJ. Verapamil in treatment-resistant mania: an open trial. J Clin Psychopharmacolol 1987:7:980-2.
14. Patterson JF. Treatment of acute mania with verapamil [letter]. J Clin Psychopharmacol 1987;7:206.
15. Mathis P, Schmitt L, Moron P. Efficacité du verapamil dans les accès maniaques. Encephale 1988;XIV;127-32.
16. Dinan TG, Silverstone T, Cookson JC, Cortisol, prolactin, and growth hormone levels with clinical ratings in manic patients treated with verapamil. Int Clin Psychopharmacol 1988;3:151-6.
17. Brunet G, Cerlich B, Robert P, Dumas S, Soutre F, Darcourt G. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin Neuropharmacol 1990;13:224-8.
18. Johnson BA, Cowen PJ. Calcium channel blockade and resistant bipolar depression. Irish Journal of Psychological Medicine 1991;8:50-1.
19. Lindelius R, Nilsson CG. Flunarizine as maintenance treatment of a patient with bipolar disorder. Am J Psychiatry 1992;149:139.
20. De Beaurepaire R. Treatment of neuroleptic resistant mania and schizoaffective disorders. Am J Psychiatry 1992;149:1614.
21. Goodnick PJ. Verapamil prophylaxis in pregnant women with bipolar disorder. Am J Psychiatry 1993;150:150-6.
22. Lenzi A, Maraziti D, Rattaelli S, Cassano GB. Effectiveness of combination verapamil and chlorpromazine in the treatment of severe manic or mixed manic patients. Prog Neuropsychopharmacol Biol Psychiatr 1996;20;419-26.
23. Grunze H, Walden J, Wolf R, Berger M. Combined treatment with lithium and nimodipine in a bipolar I manic syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1996:29;419-26.
24. Goodnick PJ. Treatment of mania: relationship between response to verapamil and changes in plasma calcium and magnesium levels. South Med J 1996;89:225-6.
25. Pollack MH, Rosenbaum JF. Verapamil in the treatment of recurrent unipolar depression. Biol Psychiatry 1978;22:779-82.
26. Kramer MS, Kaputo K, Di Johnson C, Maldonado L, Mired A, Sheues P, and others. Negative trial of nifedipine in depression. Biol Psychiatry 1988;24:958-9.
27. Hullet FT, Potkin SG, Levy AB, Ciasca R. Depression associated with nifedipine-induced calcium channel blockers. Am J Psychiatry 1988;145:1277-9.
28. Eccleston D, Cole AJ. Calcium-channel blockade and depressive illness. Br J Psychiatry 1990;156:889-91.
29. Jacques RM, Cox SJ. Verapamil in major (psychotic) depression [letter]. Br J Psychiatry 1991;158:124-5.
30. Walden J, Fritze J, VanCalker D, Berger M, Grunze H. A calcium channel antagonist for the treatment of depressive episodes: single case reports. J Psychiatr Res 1995;29:71-6.
31. Pickar D, Wolkwitz O, Doran A, Labarco R, Roy A, Breier A, and others. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 1987;44:113-9.
32. Bartko G, Horvath S, Zador G, Frecska E. Effects of adjuntive verapamil administration in chronic schizophrenic patients. Prog Neuropharmacol Biol Psychiatry 1991;15:343-9.
33. Schepelern S, Kester A. Verapamil in treatment of severe schizophrenia. Acta Psychiatr Scand 1987;75:557-8.
34. Steadman TJ, Whiteford HA, Eyles BL, Welham JL, Pond SM. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. J Clin Psychopharmacol 1991;11:43-7.
35. Torjman SV, Bloom DM, Vasavan Nair NP. Verapamil in the treatment of chronic schizophrenia. Psychopharm Bull 1987;23:227-9.
36. Barrow N, Childs A. An anti-tardive dyskinesia effect of verapamil. Am J Psychiatry 1986;143:1485.
37. Leys D, Vermersch P, Daniel T, Comgras S, Goudemand M, Caron J, and others. Diltiazem for tardive dyskinesia. Lancet 1988;1:250-1.
38. Reiter S, Adler R, Angrist B, Peselow E, Rotrosen J. Effect of verapamil on tardive dyskinesia and psychosis in schizophrenic patients [letter]. J Clin Psychiatry 1989;50:26-7.
39. Goldstein JA. Nifedipine treatment of Tourette's syndrome [letter]. J Clin Psychiatry 1984;45:360.
40. Berg R. A case of Tourette's syndrome treatment with nifedipine [letter]. Acta Psychiatr Scand 1985;72:400-401.
41. Walsh TI, Lavenstein B, Licamele WI, Bronheim S, O'Leary J. Calcium antagonists in the treatment of Tourette's disorder [letter]. Am J Psychiatry 1986;143:1467-8.
42. Goldstein JA. Calcium channel blockers in the treatment of panic disorders [letter]. J Clin Psychiatry 1985;46:546.
43. Klein E. Uhde TW. Controlled study of verapamil for treatment of panic disorder. Am J Psychiatry 1988;145:431-4.
44. Dubovsky SL, Franks RD, Lifschitz M, Coe P. Effectiveness of verapamil in the treatment of mania. Am J Psychiatry 1982;139;502-4.
45. Dubovsky SL, Franks AD, Schreier D. Phenelzine-induced hyupomania; effect of verapamil. Biol Psychiatry 1985;20:1009-11.
46. Deichen RF. Verapamil treatment of biopolar depression. J Clin Psychopharmacol 1990;10:148-9.
47. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993;49:257-72.
48. Goodnick P. Nimodipine treatment of rapid cycling bipolar disorder. J Clin Psychiatry 1995;56:330.
49. Hoschl C. Verapamil for depression? Am J Psychiatry 1983;140:1100.
50. Uhr SB, Jackson K, Berger PA, Csernansky JG. Effects of verapamil administration on negative symptoms of chronic schizophrenia. Psychiatry Res 1988;23:351-2.
51. Giannini AJ, Houser WL Jr, Loiselle RH, Giannini MC, Price WA. Antimanic effects of verapamil. Am J Psychiatry 1984;141:1602-3.
52. Giannini AJ, Loiselle RH, Price WA, Giannini MC. Comparison of antimanic efficacy of clonidine and verapamil. J Clin Pharmacol 1985;25:307-8.
53. Dubovky S, Franks RD, Allen S, Murphy J. Calcium antagonists in mania: a double blind study of verapamil. Psychiatry Res 1986;18:309-20.
54. Dose M, Emrich HM, Cording-Tommel C, von Zerssen D. Use of calcium antagonists in mania. Psychoneuroendocrinology 1986;11:241-3.
55. Janicak PG, Sharma RP, Pandey G, Davis JM. Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. Am J Psychiatry 1998;155:972-3.
56. Giannini AJ, Taraszewski R, Loiselle RH. Verapamil and lithium as maintenance therapy of manic patients. J Clin Pharmacology 1987;27:980-2.
57. Garza-Trevino ES, Overall JE, Hollister LE. Verapamil versus lithium in acute mania. Am J Psychiatry 1992;149:121-2.
58. Walton SA, Berk M, Brook S. Superiority of lithium over verapamil in mania: a randomized controlled trial. J Clin Psychiatry. 1996;57:543-6.
59. Hoschl C, Kozemy J. Verapamil in affective disorders: a controlled, double-blind study. Biol Psychiatry 1989;25:128-40.
60. Grebb JA, Shelton RC, Taylor EH, Bigelow. A negative double-blind placebo-controlled trial of verapamil in chronic schizophrenia. Biol Psychiatry 1986;21:691-4.
61. Price WA. Antipsychotic effects of verapamil in schizophrenia. Hillside Hospital Journal of Clinical Psychiatry 1987;9:225-30.
62. Yamada K, Kanba S, Ashikari I, Ohnishi K, Yagi G, Asai M. Nivaldipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. J Clin Psychopharmacol 1987;7:195-6.
63. Kramer MS, DeMaria P, Morrow R, DiJohnson C, Sheves P. Nifedipine in neuroleptic-refractory schizophrenia. J Clin Psychopharmacol 1987;7:195-6.
64. Schwartz BL, Fay-MacCarthy M, Kendrick K, Rosse RB, Deutsch SI. Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia. J Clin Neuropharmacol 1997;20:354-70.
65. Ban TA, Morey I, Aguglia E, Azzserelli O, Balsana F, Masrigliano V, and others. Nimodipine in the treatment of old age dementia. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:525-51.
66. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1991;27:1133-42.
67. Walker FO, Young Ab, Rodnitsky RL. Diltiazem in Huntington's disease [letter]. Neurology 1985;25(Suppl 1):177.
68. Goldstein JA, Calcium channel blockers in the treatment of panic disorders [letter]. J Clin Psychiatry 1985;46:546.
69. Dubovsky SL. Why don't we hear more about the calcium antagonists? [letter]. Biol Psychiatry 1994;35:149-50.
70. Furberg CD, Psaty BM. Nifedipine-dose related increase in mortality in patients with coronary heart disease [letter]. Circulation 1996;93:1475-6.
71. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers incrase the risk of cancer? Am J Hypertens 1996;9:659-99.
72. Dubovsky SI. Calcium channel antagonists as novel agents for manic-depressive disorder. In: Schatzberg AF, Nemeroff CB, editors. Textbook of Psychopharmacology. 2nd ed. Washington (DC): American Psychiatric Press; 1998. p 455-69.
73. ** antagonists. Human Psychopharmacology Clinical Experimental 1998;13:389-405.